Cupid Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
- Paid Up Capital ₹ 6.29 M
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.25 Cr
- Revenue Growth -15.38%
- Profit Growth 302.29%
- Ebitda -17.41%
- Net Worth 19.96%
- Total Assets 27.01%
About Cupid Bio-Tech
Cupid Bio-Tech Limited (CBL) is a Public Limited Indian Non-Government Company incorporated in India on 21 April 1995 and has a history of 29 years and nine months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 6.29 M.
The company currently has active open charges totaling ₹5.25 Cr.
Bipinkumar Ganatra, Deepak Shah, and Ganatra Mangaldas serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U01135GJ1995PLC025560
-
Company No.
025560
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
21 Apr 1995
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Cupid Bio-Tech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bipinkumar Ganatra
|
Director | 05-May-1995 | Current |
|
Deepak Shah
|
Director | 13-Aug-2021 | Current |
|
Ganatra Mangaldas
|
Director | 05-May-1995 | Current |
Financial Performance of Cupid Bio-Tech.
Cupid Bio-Tech Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 15.38% decrease. The company also saw a substantial improvement in profitability, with a 302.29% increase in profit. The company's net worth Soared by an impressive increase of 19.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cupid Bio-Tech?
In 2020, Cupid Bio-Tech had a promoter holding of 43.61% and a public holding of 56.39%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.25 Cr
₹0
Charges Breakdown by Lending Institutions
- Citibank N.A. : 5.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Aug 2004 | Citibank N.A. | ₹5.25 Cr | Open |
How Many Employees Work at Cupid Bio-Tech?
Unlock and access historical data on people associated with Cupid Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cupid Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cupid Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
